Small cell transformation (SCT) is a known acquired resistance mechanism to targeted therapies in non-small cell lung cancer (NSCLC) but has not been reported following HER2 tyrosine kinase inhibitor (TKI) therapy. We report the first case of SCT detected during acquired resistance to zongertinib, a novel selective...
D. Zheng, Hai-Yan Xu, Yan Wang· Frontiers in Oncology· 0 citations
Her2-mutant NSCLC constitutes a distinct subtype characterized by unique clinicopathological and molecular features and for postoperative patients presenting with advanced disease or an increased burden of high-risk recurrence factors, more aggressive therapeutic strategies should be considered.
Guang-Jian Yang, Linyan Tian, Xiao-Yong Tang et al.· Current Cancer Drug Targets· 0 citations
